Chiba, Japan

Tetsuya Terasaki

This inventor holds 1 USPTO granted patent. Top assignee: Kabushiki Kaisha Yakult Honsha. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tetsuya Terasaki. Retrieved from https://idiyas.com/inventor/tetsuya-terasaki-imtw4jy3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tetsuya Terasaki: Innovator in Peptide Research

Introduction

Tetsuya Terasaki is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of peptide research, particularly in the development of nootropic agents. His work has implications for cognitive enhancement and health.

Latest Patents

Terasaki holds a patent for peptides and nootropic agents. This innovation showcases his commitment to advancing scientific knowledge and practical applications in the field of biochemistry.

Career Highlights

Tetsuya Terasaki is associated with Kabushiki Kaisha Yakult Honsha, a company known for its dedication to health and nutrition. His role there has allowed him to explore and develop innovative solutions that benefit society.

Collaborations

Terasaki has worked alongside esteemed colleagues such as Shuichi Tanabe and Yoshiyuki Shishido. Their collaborative efforts have further enriched the research environment and fostered innovation.

Conclusion

Tetsuya Terasaki's contributions to peptide research and nootropic agents highlight his role as a significant inventor in the scientific community. His work continues to inspire advancements in health and cognitive enhancement.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…